Abstract: The present invention provides methods of preparing solid dosage form, particularly pharmaceutical dosage forms, using extrusion and 3D-printing, as well as the solid dosage form itself, the compositions used to make said items, uses of the solid dosage forms, and containers used in their preparation.

Abstract: The present invention relates to methods and apparatuses for estimating the status of a bladder, especially with respect to the likelihood of an imminent voiding of the bladder. The apparatuses carry out computer-implemented methods of estimating a bladder status employing a bladder monitor which collects bladder data (e.g. using ultrasound) and transmits the bladder data to a data processor for algorithmic conversion to a bladder status. Such algorithms may be trained and tuned to a particular person's bladder. Having established a bladder status based on otherwise esoteric bladder data, the data processor may then trigger an alert signal where the bladder status meets particular criteria indicating an imminent voiding event. Such a trigger signal may be used to alert a nocturnal enuresis patient to an impending void so that they can be awoken before any bedwetting occurs.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention relates to solid dosage forms comprising coatings based on natural ingredients, such as naturally-occuring esterified and non-esterified polyuronic acids, optionally in combination with stabilising lipophilic component(s) (e.g. surfactant(s)) and/or other stabilising components. The inventors have made the surprising discovery that polysaccharide-based coatings can be stabilised, and often imparted with gastric resistant properties, through the inclusion of particular additives and/or additional layers. In particular, polyuronic acid-containing coatings may be stabilised and rendered more robust through the inclusion of a lipophilic component (e.g. surfactant), an esterified polyuronic acid, and/or the deployment of an additional coating layer containing stabilising agents that affect the disintegration and/or dissolution of the polyuronic acid.

Abstract: The present invention relates to a solid composition which contains a mixture of liquid oil and solid lipid. The solid lipid acts as a solid carrier vehicle for the oil thereby permitting oils to be provided, at relatively high loading, in solid form.

Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention relates to a solid composition which contains a mixture of liquid oil and solid lipid. The solid lipid acts as a solid carrier vehicle for the oil thereby permitting oils to be provided, at relatively high loading, in solid form.

Abstract: The present invention utilises 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilises novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalised medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparatuses to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention relates to solid dosage forms comprising coatings based on natural ingredients, such as naturally-occuring esterified and non-esterified polyuronic acids, optionally in combination with stabilising lipophilic component(s) (e.g. surfactant(s)) and/or other stabilising components. The inventors have made the surprising discovery that polysaccharide-based coatings can be stabilised, and often imparted with gastric resistant properties, through the inclusion of particular additives and/or additional layers. In particular, polyuronic acid-containing coatings may be stabilised and rendered more robust through the inclusion of a lipophilic component (e.g. surfactant), an esterified polyuronic acid, and/or the deployment of an additional coating layer containing stabilising agents that affect the disintegration and/or dissolution of the polyuronic acid.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: The present invention relates to a solid form, particularly to a 3D-printed immediate release solid dosage form (e.g. based on a pharmaceutical, nutraceutical, or food supplement composition). To overcome some of the solubility and disintegration problems inherited by 3D-printed solid dosage forms, the solid form comprises one or more channels, generally in the form of tubular passages or grooves, through the body of the solid form or the surface thereof.

Abstract: A retaining device for a flexible line, comprising a first member (100), a second member (200) moveably attachable to the first member, and a guiding means (110, 210) positioned on either or both of the first member (100) and the second member (200). The first member has a first retaining portion (400) positioned on a first retaining surface (100a) of the first member. The second member has a second retaining portion (400) positioned on a second retaining surface (200a) of the second member. The first retaining portion and the second retaining portion are each configured to retain a flexible line, and the guiding means (110, 210) is configured to determine the curvature of the flexible line to inhibit kinking of the flexible line when retained by the first retaining portion (400) and the second retaining portion (400).

Abstract: The present invention relates to a solid composition which contains a mixture of liquid oil and solid lipid. The solid lipid acts as a solid carrier vehicle for the oil thereby permitting oils to be provided, at relatively high loading, in solid form.

Abstract: The present invention relates to a powder composition, in particular a fingerprint powder composition for the visualisation of latent fingerprints. Such fingerprint powder compositions comprise carbogenic nanoparticles which, when mixed with a suitable diluent (including any existing or future fingerprint powders), exhibits excitation-dependent emission properties which enable the fingerprint powder compositions and imagable fingerprint impression patterns formed thereform to be imaged in a variety of different colours by simply varying the wavelength(s) of any excitation radiation. As certain backgrounds can render visualisation of fingerprint impression patterns very difficult, having the flexibility to judiciously tune the foreground colour of the fingerprint impression patterns is a significant advantage since it permits instantaneous improvements in visualisation without needing to resort to using a different fingerprint powder.

Abstract: Provided are methods and kits that allow the amplification, in a single multiplex reaction, of the thirteen rapidly mutating Y chromosome short tandem repeats (RM Y-STRs) at loci DYF387S1; DYF399S1; DYF403S1a/b; DYF404S1; DYS449; DYS518; DYS526a/b; DYS547; DYS570; DYS576; DYS612; DYS626; and DYS627, if present in a sample of DNA, and determination of the alleles at these RM Y-STRs. The ability to achieve such determination through a single multiplex arises as a result of a beneficially designed set of primers disclosed herein. Optimised conditions for the PCR also contribute to the advantages observed. Such kits and methods may be of benefit in the context of forensic sciences.

Abstract: The present invention relates to methods of diagnosing and/or prognosing proliferative disorders, especially brain cancers (e.g. gliomas). In particular, the present invention provides a means to conveniently detect malignant tumors merely by assaying or analyzing blood (particularly blood serum). Cytokines and/or angiogenesis factors in blood serum have been found to be surprisingly powerful at indicating the presence of brain cancers in a subject. Moreover, spectroscopic analysis, especially ATR-FTIR analysis, of a blood sample has been demonstrated to be surprisingly effective at producing a signature that can be correlated with the presence, extent, severity, or aggressiveness of malignant tumors in a subject.